First report on the pharmacokinetic profile of nimbolide, a novel anticancer agent in oral and intravenous administrated rats by LC/MS method

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 1092, Issue , 2018, Pages 191-198

  Baira, Shandilya Mahamuni ^a   Khurana, Amit ^a   Somagoni, Jaganmohan ^b   Srinivas, R ^a,c   Godugu, Chandraiah ^a   Talluri, M V N Kumar ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b ClinSync Clinical Research Pvt Ltd   (India)

^c INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Absorption; LC QTOF MS; Nimbolide; Oral bioavailability; Pharmacokinetics

Indexed keywords

ABSORPTION; BIOCHEMISTRY; DRUG INTERACTIONS; LIQUID CHROMATOGRAPHY; PETROLEUM RESERVOIR EVALUATION; PRECIPITATION (CHEMICAL); RATS;

CHROMATOGRAPHIC SEPARATIONS; INTRAVENOUS ADMINISTRATION; LC/QTOF/MS; NIMBOLIDE; ORAL BIOAVAILABILITIES; PHARMACOKINETIC PROFILES; PHYSICOCHEMICAL PROPERTY; TRADITIONAL MEDICINAL PLANTS;

PHARMACOKINETICS;

ACETONITRILE; FORMIC ACID; NIMBOLIDE; REGORAFENIB; WATER; ANTINEOPLASTIC AGENT; LIMONOID;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG INTERACTION; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIMIT OF QUANTITATION; LIPOPHILICITY; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; ORAL ABSORPTION; PHARMACOKINETIC PARAMETERS; PHYSICAL CHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; PLATE COUNT; PRIORITY JOURNAL; RAT; RETENTION TIME; STANDARD; THERAPY DELAY; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION; ANIMAL; BLOOD; CHEMISTRY; DRUG STABILITY; INTRAVENOUS DRUG ADMINISTRATION; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; ORAL DRUG ADMINISTRATION; PROCEDURES; REPRODUCIBILITY; SPRAGUE DAWLEY RAT; STATISTICAL MODEL;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, LIQUID; DRUG STABILITY; LIMIT OF DETECTION; LIMONINS; LINEAR MODELS; MALE; MASS SPECTROMETRY; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS;

EID: 85048321192     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2018.06.002     Document Type: Article

References (25)

1. Kumar, V.S., Navaratnam, V., Neem (Azadirachta indica): prehistory to contemporary medicinal uses to humankind. Asian Pacif. J. Tropi. Biomed. 3 (2013), 505–514.
2. Champagne, D.E., Koul, O., Isman, M.B., Scudder, G.G., Towers, G.N., Biological activity of limonoids from the rutales. Phytochemistry 31 (1992), 377–394.
3. Govindachari, T., Chemical and biological investigations on Azadirachta indica (the neem tree). Curre. Sci. Bang. 63 (1992), 117–122.
4. Kumar, P.S., Mishra, D., Ghosh, G., Panda, C.S., Biological action and medicinal properties of various constituent of Azadirachta indica (Meliaceae): an overview. Anna. Biologi. Res. 1 (2010), 24–34.
5. Rochanakij, S., Thebtaranonth, Y., Yenjai, C., Yuthavong, Y., Nimbolide, a constituent of Azadirachta indica, inhibits plasmodium falciparum in culture. The South. Asian J. Tropi. Medi. Pub. Heal. 16 (1985), 66–72.
6. Suresh, G., Gopalakrishnan, G., Wesley, S.D., Pradeep Singh, N., Malathi, R., Rajan, S., Insect antifeedant activity of tetra nortriterpenoids from the rutales. A perusal of structural relations. J. Agric. Food Chem. 50 (2002), 4484–4490.
7. Cohen, E., Quistad, G.B., Jefferies, P.R., Casida, J.E., Nimbolide is the principal cytotoxic component of neem-seed insecticide preparations. Pest Manag. Sci. 48 (1996), 135–140.
8. Rojanapo, W., Suwanno, S., Somjaree, R., Glinsukon, T., Thebtaranont, Y., Mutagenic and antibacterial activity testing of nimbolide and nimbic acid. J. Sci. Soc. Thail. 11 (1985), 177–181.
9. Gupta, S.C., Prasad, S., Sethumadhavan, D.R., Nair, M.S., Mo, Y.Y., Aggarwal, B.B., Nimbolide, a limonoid triterpene, inhibits growth of human colorectal cancer xenografts by suppressing the proinflammatory microenvironment. Clinic. Canc. Res. 19 (2013), 4465–4476.
10. Priyadarsini, R.V., Murugan, R.S., Sripriya, P., Karunagaran, D., Nagini, S., The neem limonoids azadirachtin and nimbolide induce cell cycle arrest and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells. Free Radic. Res. 44 (2010), 624–634.
11. Gupta, S.C., Reuter, S., Phromnoi, K., Park, B., Hema, P.S., Nair, M., Aggarwal, B.B., Nimbolide sensitizes human colon cancer cells to TRAIL through reactive oxygen species-and ERK-dependent up-regulation of death receptors, p53, and Bax. J. Biol. Chem. 286 (2011), 1134–1146.
12. Roy, M.K., Kobori, M., Takenaka, M., Nakahara, K., Shinmoto, H., Tsushida, T., Inhibition of colon cancer (HT-29) cell proliferation by a triterpenoid isolated from Azadirachta indica is accompanied by cell cycle arrest and up-regulation of p21. Planta Med. 72 (2006), 917–923.
13. Subramani, R., Gonzalez, E., Arumugam, A., Nandy, S., Gonzalez, V., Medel, J., Camacho, F., Ortega, A., Bonkoungou, S., Narayan, M., Nimbolide inhibits pancreatic cancer growth and metastasis through ROS-mediated apoptosis and inhibition of epithelial-to-mesenchymal transition. Sci. Rep., 6, 2016.
14. Babykutty, S., PS, P., RJ, N., Kumar, M., Nair, M.S., Srinivas, P., Gopala, S., Nimbolide retards tumor cell migration, invasion, and angiogenesis by downregulating MMP-2/9 expression via inhibiting ERK1/2 and reducing DNA-binding activity of NF-κB in colon cancer cells. Mole. Carcin. 51 (2012), 475–490.
15. Bodduluru, L.N., Kasala, E.R., Thota, N., Barua, C.C., Sistla, R., Chemopreventive and therapeutic effects of nimbolide in cancer: the underlying mechanisms. Toxicol. in Vitro 28 (2014), 1026–1035.
16. Priyadarsini, R.V., Manikandan, P., Kumar, G.H., Nagini, S., The neem limonoids azadirachtin and nimbolide inhibit hamster cheek pouch carcinogenesis by modulating xenobiotic-metabolizing enzymes, DNA damage, antioxidants, invasion and angiogenesis. Free Radic. Res. 43 (2009), 492–504.
17. Wang, L., Phan, D.D.K., Zhang, J., Ong, P.S., Thuya, W.L., Soo, R.A., Wong, A.L.A., Yong, W.P., Lee, S.C., Ho, P.C.L., Sethi, G., Goh, B.C., Anticancer properties of nimbolide and pharmacokinetic considerations to accelerate its development. Oncotarget 7 (2016), 44790–44802.
18. Farooqui, N.A., Dey, A., Singh, G.N., Easwari, T.S., Development and validation of HPLC method for quantitative estimation of nimbolide in bulk and pharmaceutical dosage form. Int J Pharm Pharm Sci 6 (2014), 432–437.
19. Rout, K.K., Mishra, S.K., Development of a sensitive HPTLC method for quantification of nimbolide in Azadirachta indica and its dosage form. J. Chromatogr. Sci. 52 (2014), 1089–1094.
20. Lia, Y., Guoa, S., Huaa, T., Wangb, Y., Weia, D., Zhaoa, M., Sua, S., Duana, J., Comparative pharmacokinetics of triterpenic acids in normal and immunosuppressed rats after oral administration of Jujubae fructus extract by UPLC-MS/MS. J. Chromatogr. B 1077 (2018), 13–21.
21. Food, U., Administration, D., FDA Guidance for Industry: Bioanalytical Method Validation. 2001, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, MD.
22. Polson1, C., Sarkar, P., Incledon, B., Raguvaran, V., Grant, R., Optimization of protein precipitation based upon effectiveness of protein removal and ionization effect in liquid chromatography–tandem mass spectrometry. J. Chromatogr. B 785 (2003), 263–275.
23. Godugu, C., Patel, A.R., Doddapaneni, R., Somagoni, J., Singh, M., Approaches to improve the oral bioavailability and effects of novel anticancer drugs berberine and betulinic acid. PLoS One, 9, 2014, e89919.
24. Patel, K., Chowdhury, N., Doddapaneni, R., Boakye, C.H., Godugu, C., Singh, M., Piperlongumine for enhancing oral bioavailability and cytotoxicity of docetaxel in triple-negative breast cancer. J. Pharm. Sci. 104 (2015), 4417–4426.
25. Godugu, C., Doddapaneni, R., Safe, S.H., Singh, M., Novel diindolylmethane derivatives based NLC formulations to improve the oral bioavailability and anticancer effects in triple negative breast cancer. Eur. J. Pharm. Biopharm. 108 (2016), 168–179.